1. Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients
- Author
-
Håvard Søiland, Jennifer Gjerde, Ernst A. Lien, Kari Britt Hagen, and Tone Hoel Lende
- Subjects
medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,medicine.medical_treatment ,education ,Breast Neoplasms ,High fracture ,Comorbidity ,Institute of medicine ,Scandinavian and Nordic Countries ,Disease-Free Survival ,Fractures, Bone ,Breast cancer ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Randomized Controlled Trials as Topic ,Bone Density Conservation Agents ,Aromatase Inhibitors ,business.industry ,General surgery ,Endocrine therapy ,Hematology ,General Medicine ,University hospital ,medicine.disease ,humanities ,Surgery ,Endocrine surgery ,Tamoxifen ,Oncology ,Chemotherapy, Adjuvant ,Female ,business - Abstract
1 Stavanger University Hospital, Department of Surgery, Section for Breast and Endocrine Surgery, Stavanger, Norway, 2 University of Bergen, Institute of Medicine, Bergen, Norway, 3 University of Bergen, Institute of Surgical Sciences, Bergen, Norway, 4 Haukeland University Hospital, Department of Breast and Endocrine Surgery, Bergen, Norway and 5 Haukeland University Hospital, Hormonlaboratoriet, Bergen, Norway
- Published
- 2012
- Full Text
- View/download PDF